Efficacy and safety of febuxostat in the treatment of hyperuricemia in stable kidney transplant recipients
Tadashi Sofue,1 Masashi Inui,2 Taiga Hara,1 Yoko Nishijima,1 Kumiko Moriwaki,1 Yushi Hayashida,3 Nobufumi Ueda,3 Akira Nishiyama,4 Yoshiyuki Kakehi,3 Masakazu Kohno1 1Division of Nephrology and Dialysis, Department of Cardiorenal and Cerebrovascular Medicine, Kagawa University, Kagawa, 2Department o...
Main Authors: | , , , , , , , , , |
---|---|
Format: | Article in Journal/Newspaper |
Language: | English |
Published: |
Dove Medical Press
2014
|
Subjects: | |
Online Access: | https://doaj.org/article/3a4c1bc439af46ca88ece2de86e69bcf |
id |
ftdoajarticles:oai:doaj.org/article:3a4c1bc439af46ca88ece2de86e69bcf |
---|---|
record_format |
openpolar |
spelling |
ftdoajarticles:oai:doaj.org/article:3a4c1bc439af46ca88ece2de86e69bcf 2023-05-15T18:31:02+02:00 Efficacy and safety of febuxostat in the treatment of hyperuricemia in stable kidney transplant recipients Sofue T Inui M Hara T Nishijima Y Moriwaki K Hayashida Y Ueda N Nishiyama A Kakehi Y Kohno M 2014-02-01T00:00:00Z https://doaj.org/article/3a4c1bc439af46ca88ece2de86e69bcf EN eng Dove Medical Press http://www.dovepress.com/efficacy-and-safety-of-febuxostat-in-the-treatment-of-hyperuricemia-in-peer-reviewed-article-DDDT https://doaj.org/toc/1177-8881 1177-8881 https://doaj.org/article/3a4c1bc439af46ca88ece2de86e69bcf Drug Design, Development and Therapy, Vol 2014, Iss default, Pp 245-253 (2014) Therapeutics. Pharmacology RM1-950 article 2014 ftdoajarticles 2022-12-30T21:40:56Z Tadashi Sofue,1 Masashi Inui,2 Taiga Hara,1 Yoko Nishijima,1 Kumiko Moriwaki,1 Yushi Hayashida,3 Nobufumi Ueda,3 Akira Nishiyama,4 Yoshiyuki Kakehi,3 Masakazu Kohno1 1Division of Nephrology and Dialysis, Department of Cardiorenal and Cerebrovascular Medicine, Kagawa University, Kagawa, 2Department of Urology, Tokyo Women's Medical University, Tokyo, 3Department of Urology, 4Department of Pharmacology, Kagawa University, Kagawa, Japan Background: Post-transplant hyperuricemia (PTHU), defined as serum uric acid concentration ≥7.0 mg/dL or need for treatment with allopurinol or benzbromarone, reduces long-term allograft survival in kidney transplant recipients. Febuxostat, a new nonpurine selective xanthine oxidase inhibitor, is well tolerated in patients with moderate renal impairment. However, its efficacy and safety in kidney recipients with PTHU is unclear. We therefore assessed the efficacy and safety of febuxostat in stable kidney transplant recipients with PTHU. Methods: Of 93 stable adult kidney transplant recipients, 51 were diagnosed with PTHU (PTHU group) and 42 were not (NPTHU group). Of the 51 patients with PTHU, 26 were treated with febuxostat (FX group) and 25 were not (NFX group), at the discretion of each attending physician. One-year changes in serum uric acid concentrations, rates of achievement of target uric acid (<6.0 mg/dL), estimated glomerular filtration rates in allografts, and adverse events were retrospectively analyzed in the FX, NFX, and NPTHU groups. Results: The FX group showed significantly greater decreases in serum uric acid (-2.0±1.1 mg/dL versus 0.0±0.8 mg/dL per year, P<0.01) and tended to show a higher rate of achieving target uric acid levels (50% versus 24%; odds ratio 3.17 [95% confidence interval 0.96–10.5], P=0.08) than the NFX group. Although baseline allograft estimated glomerular filtration rates tended to be lower in the FX group than in the NFX group (40±14 mL/min/1.73 m2 versus 47±19 mL/min/1.73 m2), changes in allograft estimated glomerular filtration rate ... Article in Journal/Newspaper taiga Directory of Open Access Journals: DOAJ Articles |
institution |
Open Polar |
collection |
Directory of Open Access Journals: DOAJ Articles |
op_collection_id |
ftdoajarticles |
language |
English |
topic |
Therapeutics. Pharmacology RM1-950 |
spellingShingle |
Therapeutics. Pharmacology RM1-950 Sofue T Inui M Hara T Nishijima Y Moriwaki K Hayashida Y Ueda N Nishiyama A Kakehi Y Kohno M Efficacy and safety of febuxostat in the treatment of hyperuricemia in stable kidney transplant recipients |
topic_facet |
Therapeutics. Pharmacology RM1-950 |
description |
Tadashi Sofue,1 Masashi Inui,2 Taiga Hara,1 Yoko Nishijima,1 Kumiko Moriwaki,1 Yushi Hayashida,3 Nobufumi Ueda,3 Akira Nishiyama,4 Yoshiyuki Kakehi,3 Masakazu Kohno1 1Division of Nephrology and Dialysis, Department of Cardiorenal and Cerebrovascular Medicine, Kagawa University, Kagawa, 2Department of Urology, Tokyo Women's Medical University, Tokyo, 3Department of Urology, 4Department of Pharmacology, Kagawa University, Kagawa, Japan Background: Post-transplant hyperuricemia (PTHU), defined as serum uric acid concentration ≥7.0 mg/dL or need for treatment with allopurinol or benzbromarone, reduces long-term allograft survival in kidney transplant recipients. Febuxostat, a new nonpurine selective xanthine oxidase inhibitor, is well tolerated in patients with moderate renal impairment. However, its efficacy and safety in kidney recipients with PTHU is unclear. We therefore assessed the efficacy and safety of febuxostat in stable kidney transplant recipients with PTHU. Methods: Of 93 stable adult kidney transplant recipients, 51 were diagnosed with PTHU (PTHU group) and 42 were not (NPTHU group). Of the 51 patients with PTHU, 26 were treated with febuxostat (FX group) and 25 were not (NFX group), at the discretion of each attending physician. One-year changes in serum uric acid concentrations, rates of achievement of target uric acid (<6.0 mg/dL), estimated glomerular filtration rates in allografts, and adverse events were retrospectively analyzed in the FX, NFX, and NPTHU groups. Results: The FX group showed significantly greater decreases in serum uric acid (-2.0±1.1 mg/dL versus 0.0±0.8 mg/dL per year, P<0.01) and tended to show a higher rate of achieving target uric acid levels (50% versus 24%; odds ratio 3.17 [95% confidence interval 0.96–10.5], P=0.08) than the NFX group. Although baseline allograft estimated glomerular filtration rates tended to be lower in the FX group than in the NFX group (40±14 mL/min/1.73 m2 versus 47±19 mL/min/1.73 m2), changes in allograft estimated glomerular filtration rate ... |
format |
Article in Journal/Newspaper |
author |
Sofue T Inui M Hara T Nishijima Y Moriwaki K Hayashida Y Ueda N Nishiyama A Kakehi Y Kohno M |
author_facet |
Sofue T Inui M Hara T Nishijima Y Moriwaki K Hayashida Y Ueda N Nishiyama A Kakehi Y Kohno M |
author_sort |
Sofue T |
title |
Efficacy and safety of febuxostat in the treatment of hyperuricemia in stable kidney transplant recipients |
title_short |
Efficacy and safety of febuxostat in the treatment of hyperuricemia in stable kidney transplant recipients |
title_full |
Efficacy and safety of febuxostat in the treatment of hyperuricemia in stable kidney transplant recipients |
title_fullStr |
Efficacy and safety of febuxostat in the treatment of hyperuricemia in stable kidney transplant recipients |
title_full_unstemmed |
Efficacy and safety of febuxostat in the treatment of hyperuricemia in stable kidney transplant recipients |
title_sort |
efficacy and safety of febuxostat in the treatment of hyperuricemia in stable kidney transplant recipients |
publisher |
Dove Medical Press |
publishDate |
2014 |
url |
https://doaj.org/article/3a4c1bc439af46ca88ece2de86e69bcf |
genre |
taiga |
genre_facet |
taiga |
op_source |
Drug Design, Development and Therapy, Vol 2014, Iss default, Pp 245-253 (2014) |
op_relation |
http://www.dovepress.com/efficacy-and-safety-of-febuxostat-in-the-treatment-of-hyperuricemia-in-peer-reviewed-article-DDDT https://doaj.org/toc/1177-8881 1177-8881 https://doaj.org/article/3a4c1bc439af46ca88ece2de86e69bcf |
_version_ |
1766214671478554624 |